Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery

L P Perrault1, A Y Denault, M Carrier

  • 1Department of Surgery, Montreal Heart Institute, Quebec, Canada. lpperrau@icm.umontreal.ca

Insights

Postoperative delirium after cardiac surgery can be treated with haloperidol. However, this case report highlights a rare risk of torsades de pointes, a dangerous heart arrhythmia, associated with high-dose haloperidol use in patients following coronary artery bypass grafting.

Area of Science:

  • Cardiology
  • Pharmacology
  • Intensive Care Medicine

Background:

  • Postoperative delirium is a common complication following major cardiac surgery, such as coronary artery bypass grafting (CABG).
  • Haloperidol is frequently used in intensive care units for managing delirium and is generally considered safe, even at high doses.
  • Malignant ventricular arrhythmias, including torsades de pointes, are rarely associated with haloperidol use.

Observation:

  • A patient undergoing triple bypass surgery developed delirium requiring high-dose intravenous haloperidol for psychomotor agitation.
  • Torsades de pointes occurred on the third postoperative day.
  • The arrhythmia developed in the absence of QT prolongation or other identifiable etiological factors, suggesting a direct link to haloperidol administration.

Findings:

  • High-dose haloperidol administration in the context of postoperative delirium after myocardial revascularization can precipitate torsades de pointes.
  • This specific adverse event occurred without the typical precursor of QT prolongation.

Implications:

  • Clinicians must be aware of this rare but serious complication when prescribing haloperidol to post-CABG patients.
  • Judicious use of haloperidol is crucial in this patient population due to the potential for life-threatening arrhythmias.
  • The underlying cardiac condition in post-CABG patients can exacerbate the consequences of such arrhythmias.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...